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ABSTRACT 
 
 The pathophysiology of Alzheimer’s disease (AD) remains difficult to precisely 
ascertain in part because animal models fail to fully recapitulate many aspects of the 
disease and postmortem studies do not allow for the study of the pathophysiology. In 
vitro models of AD generated with patient derived human induced pluripotent stem cells 
(hiPSCs) could provide new insight into disease mechanisms. Although many protocols 
exist to differentiate hiPSCs to neurons, standard practice relies on two-dimensional (2-
D) systems, which do not accurately mimic the complexity and architecture of the in vivo 
brain microenvironment. This research aims to create three-dimensional (3-D) models of 
AD using hiPSCs, which would enhance the understanding of AD pathophysiology 
thereby, enabling the generation of effective therapeutics. 
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CHAPTER 1: Introduction 
1.1.1 Motivation 
 Alzheimer’s disease (AD) is the sixth leading cause of death in the United States, 
with a 71% increase in deaths between the years 2000 and 20131. In the United States 
alone there are an estimated 5.4 million people that suffer from Alzheimer’s disease, with 
a new case arising every thirty three seconds and an expected 2.5 fold increase in cases 
by mid-century2. The complex pathophysiology of Alzheimer’s disease leads to a 
difficulty in finding a cure or even an effective treatment method. For this reason, it is 
imperative to develop a model of Alzheimer’s that fully recapitulates all of the 
complexities of the disease. 
1.1.2 Alzheimer’s Disease  
  Alzheimer’s disease is the most common form of dementia, which can be defined as 
the loss of cognitive functioning and behavioral abilities to the point where it interferes 
with a person’s daily life3. This loss of cognitive functioning and behavioral abilities is 
irreversible, again highlighting the need for a closer study at Alzheimer’s disease.  The 
disease is progressive, leading to in increase in dementia symptoms over time. The 
progression is grouped into three main stages based on the severity of the impairment4. 
The “early stage” refers to mild Alzheimer’s disease during which individuals have mild 
impairment but can still function independently 5. The “middle stage” is the typically the 
longest stage of the disease and refers to moderate Alzheimer’s during which the 
symptoms will be more noticeable and the individual typically begins to require 
assistance in performing daily tasks 5. The final stage is “late stage” or severe 
Alzheimer’s during which the individual loses the ability to respond to their environment 
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and communicate, leading them to require to full time care4. This progression of the 
disease is due to the development of extracellular amyloid beta plaques and intracellular 
neurofibrillary tangles in different regions of the brain (Fig1-1). These plaques and 
tangles are the two pathological hallmarks of Alzheimer’s disease6. The insoluble plaques 
are formed from beta amyloid fragments aggregating together, causing a neurotoxic 
environment. The plaques block ion channels, disrupt calcium homeostasis, cause 
mitochondrial oxidative stress, impair energy metabolism, and cause abnormal glucose 
regulation, which all lead to neuronal cell death7. The tangles are formed from 
hyperphosphorylation of tau, a microtubule associated protein. The hyperphosphorylation 
of tau results in microtubule destabilization and ultimately apoptosis of neurons7. The 
excess accumulation of amyloid beta plaques are hypothesized to lead to neurofibrillary 
tangles, and together these contribute to Alzheimer’s disease8 (Fig 1-2).  
1.1.3 Familial Versus Sporadic Alzheimer’s Disease 
 Alzheimer’s disease is divided into two forms: familial (FAD) and sporadic (SAD). 
While the familial form is due to mutations in three major genes (amyloid precursor 
protein (APP) gene, presenelin1 (PSEN1) gene, and presenilin2 (PSEN2) gene), the 
sporadic form is thought to be due to a combination of genetic and environmental factors, 
including Apolipoprotein E (ApoE)9.  
 Sporadic Alzheimer’s disease accounts for 95% of all AD cases and has an estimated 
genetic component of 50%-70%, half of which is due to ApoE allele, specifically ApoE 
ε410. ApoE releases cholesterol that is used to support synaptogenesis and the 
maintenance of synaptic connections11. There are numerous studies that are attempting to 
uncover the complex mechanisms behind SAD. Although the exact pathophysiology is 
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still unknown, it is thought that ApoE ε4 either increase toxic function or decrease 
neuroprotective function, thus leading to cognitive decline12. Specifically, it has been 
hypothesized that ApoE is involved in deposition or clearance of amyloid beta by direct 
protein-to-protein interaction13.  
 Familial Alzheimer’s disease accounts for only 5% of all AD cases. FAD is due to 
mutations in the APP, PSEN1, or PSEN2 genes, which cause an increased production of 
amyloid plaques. These three gene mutations affect the cleavage of the amyloid precursor 
protein (APP) and lead to the formation of amyloid beta plaques, the first hallmark of 
Alzheimer’s disease which then gives rise to the second hallmark, neurofibrillary tangles. 
APP is either cleaved by α-secretase, which is normal cleavage, or by β- and γ- secretase, 
which is abnormal cleavage. When α-secretase cleaves APP, the cleavage occurs in the 
middle of the Aβ domain and is not amyloidogenic, but when β- and γ- secretase cleave 
APP, it does not occur in the middle of the Aβ domain and results in the release of 
neurotoxic Aβ peptides, which accumulate together into oligomer aggregates9. A 
mutation in the APP gene enables preferential cleavage by β-secretase by inhibiting α-
secretase cleavage. PSEN1 and PSEN2 are both components of the γ-secretase complex. 
As such, a mutation in either PSEN1 or PSEN2 results in an increase in γ-secretase 
cleavage (Fig 1-3). The mutations in APP, PSEN1, and PSEN2 and resulting increase in 
amyloidogenic cleavage, lead to an increase in Aβ peptide production. The excess Aβ can 
impair synaptic function between neurons and trigger inflammatory response. This leads 
to neuronal death and the Aβ plaques14.  
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1.2 Models to Study Alzheimer’s Disease 
 Alzheimer’s disease remains an elusive disease, as the mechanisms driving it are not 
yet understood. In order to gain the knowledge necessary for effective treatment and 
eventually a cure, it is imperative to study the disease in depth. There are three main 
techniques used to study AD. The first is animal models, the second is human cadaveric 
studies, and the third is the use of stem cells. The use of these various models helps in the 
understanding of AD. 
1.2.1 Animal Models 
 Animal models provide researchers with the unique opportunity to study Alzheimer’s 
disease as it is developing, thus allowing the study of the pathophysiology and 
manifestation of the disease. Animal models may also be used to study the effect of 
various drugs on the disease. As previously mentioned, the specific causes of SAD are 
not known, while FAD is associated with various gene mutations. Due to this, animal 
models have been limited to recapitulating the disease in only the familial form15.  
The standard mouse model used to study AD contains one mutation, but there has 
been advancement in the field that led to a triple transgenic mouse model. First, a tau 
transgenic mouse, which has been shown to reproduce aggregation and neurofibrillary 
tangle formation, was crossed with an APP transgenic mouse, which has been shown to 
reproduce β-amyloid plaque formation and memory impairment. Then, by combining the 
expression of APP and tau on a PSEN1 background, a triple transgenic mouse model was 
created16 (Fig 1-4). This model allows for a deeper understanding of AD, as it more 
closely recapitulates the human pathology, through the tangle and plaque formation.  
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The use of transgenic mouse models has exponentially expanded the 
understanding of disease manifestation, but there are limitations when it comes to animal 
studies. For example, the disease may manifest differently in a mouse compared to how it 
manifests in humans. Although the new triple transgenic mouse model more closely 
recapitulates the human form of the disease, it is necessary for the mouse to carry 
multiple mutations. This is not how the disease presents itself in a human; a human with 
FAD either has an APP, PSEN1, or PSEN2 mutation.  
1.2.2 Postmortem Studies 
 A second model used to study Alzheimer’s disease is postmortem studies. The need 
for postmortem studies arises from the limitations of animal models. Namely, animal 
models do not fully recapitulate human disease complexities due to genetic and 
environmental factors17. Postmortem studies allow researchers to look at the disease as it 
is presented in humans. With this, we are able to further understand the affects that 
Alzheimer’s have on the brain. However, these studies show just a snap shot of the 
disease and do not help in the understanding of the pathophysiology. There is also a 
limited amount of these samples available to study. 
1.2.3 Stem Cells 
 The previous two models of Alzheimer’s disease, animal models and postmortem 
studies, are helpful in certain aspects of the disease, but are lacking key features 
necessary to fully understanding its complexities. For animal models, the key features 
missing are that the disease is not manifested in the same way within the mouse as it is in 
humans, and the sporadic case of AD is very hard to recapitulate since the 
pathophysiology is not fully understood. For postmortem studies, the key feature missing 
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is that there is only a snapshot of the disease and it is not possible to see how the disease 
came to be. Stem cell models address these various limitations of the animal models and 
postmortem studies. There are two types of stem cells, embryonic stem cells (ESCs) and 
human induced pluripotent stem cells (hiPSCs). ESCs are derived from the inner cell 
mass of blastocysts and can indefinitely self-renew or be differentiated into different cell 
types18. This gives rise to the ability to understand disease pathophysiology through 
disease modeling, screening drugs, and cell replacement therapy. The limitation of ES 
cells is the difficulty of generating disease-specific ES cell lines. For this reason, human 
induced pluripotent stem cells (hiPSCs) and neural progenitor cells (NPCs) are used 
throughout the research being presented.  
1.2.4 Human Induced Pluripotent Stem Cells  
 Human induced pluripotent stem cells are derived from reprogramming somatic cells 
through the overexpression of the transcription factors Oct3/4, Sox2, c-Myc, and Klf419.  
With this, the ability to study the exact mechanisms behind the disease for both familial 
and sporadic cases of Alzheimer’s disease has become a possibility. The ability to 
reprogram somatic cells from familial AD, sporadic AD, and healthy individuals and then 
differentiate these cells into neurons allows for the study of the disease in both its forms 
and helps to reveal the mechanisms behind it (Fig 1-4). As with all models, these models 
still have limitations. Particularly, the in vitro culturing may not be able to mimic the in 
vivo system quite right and lead to some difficulties in revealing vital information20.  
1.2.5 Neural Progenitor Cells 
 In order to use stem cells to investigate mechanisms of neurological disorders and 
develop more physiologically relevant disease models, methods for generation of disease 
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specific neural progenitor cells are needed. NPCs are multipotent stem cells that are able 
to differentiate into the various cell types of the central nervous system21. NPCs can be 
generated from disease specific hiPSCs and provide invaluable insights into AD 
mechanisms that cannot be recapitulated in animal models and cannot be seen in the snap 
shot from postmortem studies. The benefit of using NPCs to model Alzheimer’s disease 
rather than hiPSCs comes from the fact that the NPCs are a population of cells closer to 
the final differentiated neurons and are biased to a forebrain fate.  
1.2.5.1 Materials and Methods 
1.2.5.1.1 Medias 
Various medias were used for hiPSC maintenance and NPC formation. Essential 8 
(DMEM/F12 supplemented with 543 ug/mL NaHCO3, 64 ug/mL L-Ascorbic acid-2-
phosphate, 140 ng/mL sodium selenite, 10.7 ug/mL Transferrin, 20 ug/mL insulin, 100 
ng/mL FGF2, and 2 ng/mL TGFB) is a xeno-free, defined maintenance media used for 
long-term expansion of hESCs and hiPSCs. Several neuronal differentiation medias were 
used to drive cell fate of hiPSCs into cells of the central nervous system. Neural base 
media [NBM (DMEM/F12 supplemented with 0.5% N2, 0.5% B27, and 1% GlutaMAX)] 
is supplemented with small molecules and growth factors to make the neural induction 
media [NIM (NBM supplemented with 200 ng/mL Noggin and 0.5 uM Dorsomorphin)], 
neural expansion media [NEM (NBM supplemented with 20 ng/mL basic fibroblast 
growth factor and 20g/mL epidermal growth factor)], and neural differentiation media 
[NDM (20 ng/mL brain-derived neurotrophic factor and 20 ng/mL glial-derived 
neurotrophic factor)]. 
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1.2.5.1.2 Methods 
HiPSCs were grown on Matrigel™ coated polystyrene tissue culture plates with 
E8 medium. Upon 80% confluency, cells were dissociated down to single cell using 
Accutase®. Cells were then plated at 2x106 cells per well on an ultra-low attachment 
plate in 3 mL NIM with 3 uL 5mM ROCK inhibitor (ROCKi) and placed on an orbital 
shaker at 95 RPM inside the CO2 incubator. Embryoid bodies (EBs) should aggregate in 
the wells. The first day, the total volume was brought up to 4 mL per well, and then each 
day afterward half of the medium was changed. After five days, EBs were plated on 
Matrigel™ coated polystyrene tissue culture plates to form neural rosettes. A full media 
change was performed each day. After seven days of neural rosette formation, rosettes 
were dissociated with Accutase® and replated onto poly-L-ornthine/Laminin (PLO/LN) 
coated plates in 3mL NEM and 3uL 5mM ROCKi per well.  A full media change was 
done on days 1 and 3. Upon 90% confluency, cells were passaged. After several 
passages, only NPCs will be adhered to the PLO/LN plates. The NPCs can then be 
expanded indefinitely or differentiated into cells of the CNS. To differentiate the NPCs 
into neurons, NDM was exchanged in place of NEM and changed daily for four weeks21 
(Fig1-6 A-B).   
1.2.5.1.3 Immunofluorescence Analysis 
Immunofluorescence was performed on the differentiated hiPSCs to evaluate the 
protein expression to confirm NPC and neuronal identity. NPCs and differentiated 
neurons were dissociated into single cell suspension by using Accutase® and plated onto 
Matrigel™ coated plates in NEM/ROCKi. After 24 hours, the wells were washed twice 
with PBS. The cells were fixed by adding fixation buffer to each well, followed by a 10-
 9 
minute incubation at room temperature. The wells were then again washed twice with 
PBS. The cells were permeablized by adding perm buffer to each well, followed by a 30-
minute incubation at room temperature. Primary antibodies were added to the wells and 
incubated overnight at 4°C. The wells were then washed twice with PBS and secondary 
antibodies were added to each well. After an hour incubation at room temperature in the 
dark, the wells were washed twice with PBS. Hoescht was added to each well to 
counterstain nuclei. The plate was incubated for 10 minutes at room temperature in the 
dark, followed by washing the wells twice with PBS. The cells were then imaged using a 
fluorescent microscope. 
1.2.5.1.4 Flow Cytometry Analysis 
Flow cytometry was used to determine the percent of hiPSCs that were differentiated into 
NPCs by staining the cells with SOX1, SOX2, and Nestin antibodies. To fix the NPCs, 
the cells were spun down at 5000 rpm for three minutes at 4°C and 500 uL of fixation 
buffer was added to the cell pellet after removing the supernatant. The cells were then 
incubated at room temperature in foil for thirty minutes, followed by two FACs washes. 
The cells were then permeabilized. The cells were centrifuged at 5000 rpm for three 
minutes at 4°C and 500 ul of perm buffer was added. The cells were then incubated at 
4°C on ice for thirty minutes in foil. The cells were then washed twice with FACs buffer. 
The cells were then stained with conjugated antibodies Nestin, SOX1, and SOX2 and 
allowed to sit for an hour, followed by two FACs washes. The cell pellets were then 
resuspended in 100 ul of PBS and ran on the flow cytometer. Gates were set using an 
unstained control.  
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1.2.5.2 Results 
In order to confirm that the hiPSCs were differentiated into NPCs and then into neurons, 
two assays were performed: immunofluorescence and flow. Immunofluorescence to 
confirm NPC identity used SOX1 and SOX2 antibodies, both of which are NPC markers. 
The cells were positively stained for both of these markers, indicating that the cells were 
NPCs (Fig 1-6 C). Flow cytometry was run using SOX1, SOX2, and Nestin to confirm 
NPC identity. Over 90% of the cells were positively stained for SOX1, SOX2, and 
Nestin, indicating that the hiPSCs were differentiated into NPCs (Fig 1-6 D). 
Immunofluorescence to confirm neuronal identity used MAP2 and B3T antibodies, which 
are dendrite and mature neuronal markers. The cells were stained for both MAP2 and 
B3T, indicating that the cells were differentiated into neurons (Fig 1-6 E).  
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Figure 1-1: Progression of Alzheimer’s Disease 
Amyloid beta plaques and neurofibrillary tangles accumulate in different regions of the brain during the 
three stages of Alzheimer’s disease, leading to the cognitive decline4. 
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Figure 1-2: Interrelationship Between Amyloid Beta Plaques and Neurofibrillary Tangle Formation 
Schematic depicting how extracellular amyloid beta is internalized by receptors on the cell membrane, then 
the intracellular amyloid beta leads to neurofibrillary tangle formation through tau kinase activation, 
proteasome dysfunction promotion, or caspase-3 activation8. 
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Figure 1-3: Cleavage of Amyloid Precursor Protein 
Figure depicts the non-amyloidogenic pathway versus the amyloidogenic pathway. Alpha-secretase 
cleavage of APP prevents formation of a-beta through the non-amyloidogenic pathway, while beta- and 
gamma-secretase cleavage of APP forms a-beta through amyloidogenic pathway14. 
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Figure 1-4: Triple Transgenic Mouse Model 
The triple transgenic mouse model was created by crossing APP, PSEN1, and TAU transgenic mice 
together. This triple transgenic mouse model more closely recapitulates the human form of AD16. 
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Figure 1-5: HiPSC Reprogramming for Stem Cell Modeling of Alzheimer’s Disease 
Somatic cells from a healthy control, a FAD patient, and a SAD patient can be reprogrammed and 
differentiated into neurons to model the disease, screen drugs, and for cell replacement therapy.  
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Figure 1-6 Generation and Neuronal Differentiation of Human Pluripotent Stem Cell 
(hPSC)-Derived Neural Progenitor Cells (hNPCs). (A) Schematic of protocol for the 
generation and neuronal differentiation of hPSC-derived hNPCs. (B) Phase contrast images of 
hPSCs, embryoid bodies (EBs), neural roesttes, hNPCs, and neurons. (C) Immunofluorescent and 
(D) phase contrast images of hNPCs for multipotent markers SOX1, SOX2, and NESTIN. (E) 
Immunofluorescent analysis of mature neuronal markers MAP2 and B3T from neuronal cultures 
generated from hNPCs. 
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CHAPTER 2: Two Dimensional Stem Cell Models of Alzheimer’s Disease  
2.1 Introduction 
 The use of hiPSCs has provided a unique opportunity to study Alzheimer’s disease in 
a way not possible before. The most common method of hiPSC modeling is to use a two-
dimensional (2-D) system. Primary fibroblasts can be reprogrammed from individuals 
with FAD, SAD, or a healthy individual into hiPSCs.  These hiPSCs can then be 
differentiated to study relevant phenotypes of Alzheimer’s disease22.  
2.2 Materials and Methods 
2.2.1 Two- Dimensional Differentiation of hiPSCs to Neuronal Lineage 
 HiPSCs were grown on Matrigel™ coated polystyrene tissue culture plates with E8 
medium. Upon 80% confluency, cells were dissociated down to single cell using 
Accutase®. Cells were then plated at 2x106 cells per well on an ultra-low attachment 
plate in 3 mL NIM with 3 uL 5mM ROCK inhibitor (ROCKi) and placed on an orbital 
shaker at 95 RPM inside the CO2 incubator. Embryoid bodies (EBs) should aggregate in 
the wells. The first day, the total volume was brought up to 4 mL per well, and then each 
day afterward half of the medium was changed. After five days, EBs were plated on 
Matrigel™ coated polystyrene tissue culture plates to form neural rosettes. A full media 
change was performed each day. After seven days of neural rosette formation, rosettes 
were dissociated with Accutase® and replated onto poly-L-ornthine/Laminin (PLO/LN) 
coated plates in 3mL NEM and 3uL 5mM ROCKi per well.  A full media change was 
done on days 1 and 3. Upon 90% confluency, cells were passaged. To differentiate the 
NPCs into neurons, NDM was exchanged in place of NEM and changed daily for four 
weeks21 (Fig 2-1).   
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2.3 Results 
Various assays to were performed to determine if the differentiated hiPSCs were able to 
reproduce AD phenotypes. These 2-D derived neurons generated from FAD patients 
showed increased levels of secreted Aβ, increased levels of phospho-tau, and sensitivity 
to glutamate excitotoxicity (Fig 2-2 A-C). However, phenotypes that are often associated 
with late onset such as synaptic loss or pathological hallmarks such as Aβ plaques or 
neurofibrillary tangles are absent. Moreover, when SAD patient derived hiPSCs are 
differentiated, no disease related phenotypes are observed.  
2.4 Discussions and Conclusions  
Although these 2-D systems recapitulate Alzheimer’s disease to some degree, 
they fail to show robust AD hallmarks23. The crucial limitation of 2-D culture systems is 
the simplicity of them; the brain is a complex three-dimensional system and is not 
recapitulated.  In 2-D culture systems, the amyloid beta that is secreted by the hiPCSs is 
released into the media, which is subsequently switched out everyday24 (Fig 2-3). It is 
imperative that the model being used is able to fully recapitulate all of the aspects of the 
disease, including hallmarks. It is hypothesized that a three-dimensional model would 
better provide a native brain-like environment and therefore better model AD24. It is also 
hypothesized that having a pure population of neurons of forebrain identity would help to 
recapitulate the disease and its phenotypes. Therefore, this three-dimensional model 
would need to be optimized to produce only neurons of forebrain identity. 
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Figure 2-1: Morphologies of Cell Types at Each Stage of the Protocol.  
Phase contrast images of (a) hPSCs (scale bar = 200 um), (b) day 5 EBs (scale bar = 200 um), (c) day 7 
neural rosettes (scale bar = 500 um), 9d) passage 3 NPCs (scale bar = 100 um), and (e) week 4 neurons 
(scale bar = 200 um).  
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Figure 2-2: Alzheimer’s Disease Phenotype Analysis. (A) Levels of secreted Aβ in control and FAD 
patient derived hiPSCs, (B) Levels of phosph-tau in control and FAD patient derived hiPSCs, and (C) 
Glutamate excitotoxicity of control and FAD patient derived hiPSCs. Asterisks represent statistical 
significance. 
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Figure 2-3: 2-D Versus 3-D Cell Culture Systems. 
Due to media changes, two-dimensional cell culture systems do not allow for the aggregation of amyloid 
beta, one of the pathological hallmarks. Three-dimensional cell culture systems could solve this problem by 
keeping the Aβ peptides out of the media changes 24. 
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CHAPTER 3: Development of a Three- Dimensional Model of Alzheimer’s Using 
hiPSCs 
3.1 Introduction 
 In order to model Alzheimer’s disease as accurately as possible, a model that 
recapitulates the complex microenvironment of the brain as well as the disease itself is 
required. There are two main categories for three-dimensional hiPSC modeling. The first 
is 3-D hydrogels and the second is organoids. Typically, Matrigel™ is used as the 3-D 
matrix in hydrogels, as it contains high levels of brain extracellular matrix proteins20. 
Because three-dimensional hydrogels lack the vascular systems that support oxygenation, 
nutrition, and waste removal present in in vivo tissue, these occur through diffusion. 
Therefore, the thickness of the 3-D models is very important in allowing proper diffusion. 
The hydrogels contain cells in various depths and therefore varying amounts of nutrients 
are being supplied to the cells25. Organoids are not in a matrix, allowing for even 
diffusion of nutrients to all of the cells. Organoids are capable of self-organization and 
are structurally similar to native tissue26. 
3.1.2 Development of a Basic hiPSC-Based Organoid System 
 Here, a three-dimensional organoid hiPSC model is developed to model AD. Through 
this research the gap in knowledge left by 2-D cultures and in vivo models is bridged, due 
to the fact that organoids are very close to native physiology and are much easier to 
manipulate in terms of signaling pathways and genome editing27. The development of 
this 3-D organoid system uses non-specific differentiation of hiPSCs, thus containing 
neurons of the forebrain, midbrain, and hindbrain regions.  
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3.1.3 Development of Regionally Patterned hiPSC Organoid System  
Alzheimer’s disease affects the cholinergic neurons within the basal forebrain28. 
The non-specific differentiation of the hiPSCs in the 3-D model leads to differentiation of 
neurons of all regions of the brain. In order to more closely study Alzheimer’s disease, 
the ability to generate a homogenous culture of forebrain neurons is imperative29. 
Therefore, the 3-D hiPSC model was adapted to incorporate regional patterning.  
Through research it has been found that endogenous WNT signaling gives rise to the 
heterogeneity that is seen in hiPSC differentiation30. Exogenous modulation of Wnt 
signaling has been shown to influence the regional identity of NPCs and reduces the 
heterogeneity of neuronal differentiation30 (Fig 3-1). The manipulation of Wnt signaling 
levels is done through the addition of IWP2 or CHIR. IWP2 is used to inhibit the Wnt 
pathway31, whereas CHIR is used to stimulate Wnt signaling32. Using these small 
molecules to manipulate the level of Wnt signaling allows for a homogenous population 
of neuronal cells of the forebrain region, which can then be used to study Alzheimer’s in 
a more specific way.  
3.2 Materials and Methods 
3.2.1 Non-Specific Three-Dimensional Neuronal Differentiation Using hiPSCs 
 HiPSCs were maintained on Matrigel™ coated plates until the cells reached 80% 
confluency. The hiPSCs were then dissociated into single cell using Accutase ® and 
plated at 2.0 x 106 cells per well on ultra-low attachment plates and placed on an orbital 
shaker at 95 RPM in a 37°C, 5% CO2 incubator. Media volume was 3 mL of NIM and 3 
uL 5mM ROCKi per well. The cells begin to form into embryoid bodies (EBs) on the 
first day. The EB media is exchanged with 2 mL fresh NIM everyday during the first six 
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days to force the cells down the neural ectodermal pathway using dual SMAD inhibition. 
Through this, the hiPSCs become NPCs. On the seventh day, the media is changed from 
NIM to NEM to expand the EBs.  NEM is used for 18 days, exchanging half of the media 
daily. The NPCs are proliferating during this time and growing in size. After the 
expansion phase, on day 25, the media is changed from NEM to NDM to begin to 
differentiate the NPCs into neurons and neuronal subtypes. Half of the media was 
exchanged daily. After 18 days of differentiating, on day 43, the media was switched 
from NDM to NBM. Half of the media was exchanged daily33 (Fig 3-2 A). 
3.2.2 Regionally Patterned Three-Dimensional Neuronal Differentiation Using 
hiPSCs 
HiPSCs were maintained on Matrigel™ coated plates until the cells reached 80% 
confluency. The hiPSCs were then dissociated into single cell using Accutase ® and 
plated at 2.0 x 106 cells per well on ultra-low attachment plates and placed on an orbital 
shaker at 95 RPM in a 37°C, 5% CO2 incubator to form EBs. Media volume was 3 mL of 
NIM and 3 uL 5mM ROCKi per well. To pattern the EBs, three different conditions were 
maintained. The first condition was forebrain inducing, where 0.2 uM IWP2 was added to 
the NIM media to inhibit Wnt signaling. The second condition was midbrain inducing, 
where 0.1 uM CHIR was added to the NIM media to introduce low levels of Wnt. The 
third condition was hindbrain inducing, where 0.75 uM CHIR was added to the NIM 
media to introduce high level of Wnt. These various medias are exchanged with 2 mL of 
fresh conditioned NIM everyday for the first six days. After these first days, the NPCs are 
formed with determined lineages to forebrain, midbrain, or hindbrain regions. The 
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remaining protocol to differentiate these NPCs follows that of the non-specific 3-D 
differentiation (Fig 3-2 A).  
3.2.3 Real Time Quantitative Polymerase Chain Reaction Analysis 
 Real time quantitative polymerase chain reaction (RT-qPCR) was performed at 
specific time points in order to confirm the identity of the hiPSCs throughout the 
differentiation process. For both the non-specific and the regionally patterned embryoid 
bodies, EBs were collected directly from the well and spun down in 1 mL epitubes. RNA 
isolation was performed using the NucleoSpin™ RNA kit (Macherey-Nagel) and cDNA 
was synthesized using iScript RT Supermix (BioRad). RT-qPCR was done with iTaq 
Universal SYBER Green SMX 500 (BioRad) to form the master mix. The BioRad 
CFX384 real-time PCR detection was used to run the RT-qPCR. Results were analyzed 
from the cycle threshold (CT) values using delta-delta CT method, with the fold change 
normalized to D0 samples. Results were compiled into heatmaps using the log base 10 of 
the fold change. 
3.3 Results  
Real time quantitative polymerase chain reaction was performed on the both the 
non-specific and the regionally pattened 3-D samples at various time points in order to 
confirm that the hiPSCs were differentiating from hiPCSs into neurons and neuronal 
subtypes. First, the non-specific differentiated hiPSCs were analyzed. Samples were 
taken on D0 for normalization and three samples were taken past D50, so the hiPSCs 
would be fully differentiated into neurons and neuronal subtypes. There were three panels 
of primers that the samples were run through (Fig 3-2 C). The first panel was post-mitotic 
neuron markers. These primers include MAPT, NCAM, RBFOX3, and TUBB3. It can be 
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seen that the cells are not expressing any of these markers on day zero. However, the 
samples from day 50 onward express these markers highly, specifically the cells express 
MAPT and NCAM (Fig 2-3 C). The second panel was neurotransmitter markers, which 
included ACHE, EAAT3, GABRA, GRIN2A, SLC17A7, and SLC6A4. Again, the 
samples taken on day 0 did not express these markers, but the day 50 onward samples 
showed some expression. Specifically, ACHE, GABRA, and SLC17A7 were relatively 
highly expressed in these samples, whereas EAAT3, GRIN2A, and SLC6A4 were not 
(Fig 2-3 C). The final panel was astroglial markers, which included GFAP, MBP, and 
S100B. The samples taken on day 0 showed no expression of these markers, while the 
day 50 onward samples showed some expression (Fig 2-3 C).  
Next, the 3-D regionally patterned hiPSC differentiation was analyzed using RT-
qPCR. Samples were taken on D0 for normalization and two samples from day 50 
onward were taken from each condition, so that the hiPSCs would be fully differentiated. 
The samples from all three conditions were run through various panels of primers for 
early anterior, posterior, and CNS markers (Fig 3-2 D) and then the forebrain patterned 
samples were run through a panel of mature cortical markers (Fig 3-2 E). The 200 nM 
IWP2 treated samples, which are forebrain patterned, showed high expression of 
forebrain markers, including DLX2, FOXG1, GSX2, GS2, LHX2, and SIX3, and little to 
no expression of midbrain or hindbrain markers (Fig 3-2 D). These forebrain-patterned 
samples also showed some expression of two of the mature cortical markers ASCL1 and 
EMX2 (Fig 3-2 E). The 100 nM CHIR treated samples, which are midbrain patterned, 
showed little to no expression of the forebrain or hindbrain markers, while showing 
expression of midbrain markers OTX2, EN2, and WNT1A (Fig 3-2 E). The 750 nM 
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CHIR treated samples showed expression of all three panels of markers- forebrain, 
midbrain, and hindbrain, though the expression of the hindbrain markers is the highest 
(Fig 3-2 E).  
3.4 Discussions  
 Alzheimer’s disease has a complex pathophysiology that is yet to be fully understood. 
Various models have been used to attempt to uncover these mechanisms, but due to 
limitations of each, the disease remains elusive. HiPSCs are becoming a popular way to 
study diseases in vitro, but heavily rely on 2-D substrates that do not reflect the 3-D 
complexity of native brain tissue and are therefore unable to replicate all aspects of AD.  
Therefore, the aim of this research was to develop a 3-D hiPSC model that can 
recapitulate the complexity of the brain and the disease.  
3.4.1 Three- Dimensional hiPSC Differentiation 
A 3-D organoid - based method, which provides a similar architecture to in vivo 
neural tissue, was developed as a way to model Alzheimer’s disease. Through RT-qPCR 
analysis it was found that the hiPSCs could differentiate into post-mitotic neurons, 
astroglial cells, and neurotransmitters. It is important that the hiPSCs were able to 
differentiate into all three cell types due to the fact that many AD – related neuronal 
phenotypes are mediated by their interactions and signals from astrocytes, so a model 
lacking the presence of these cells would not be able to recapitulate the disease 
accurately34. The hiPSCs were successfully differentiated into neural cells, therefore 
overcoming the two-dimensional limitations. The second hypothesis in recapitulating the 
disease in vitro was that there is a necessity for a homogenous population of neurons of 
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forebrain identity. Therefore, this protocol was adapted to create homogenous 
populations of the three regions of the brain. 
3.4.2 Regionally Patterned Three-Dimensional hiPSC Differentiation  
 Because Alzheimer’s disease is directly related to the loss of synapses and neurons in 
the forebrain, it is critical to be able to generate a homogenous neuronal culture of 
forebrain identity in order to better model the disease and understand the mechanisms 
behind it. Previous methods based on modulating the amount of Wnt signaling in two-
dimensions in order to differentiate hiPSCs into homogenous neural populations of 
specific regions were applied to the 3-D model that was developed29. RT-qPCR analysis 
revealed that manipulating Wnt levels during the neural induction phase of differentiation 
leads to more homogenous samples of the three brain regions. IWP2 treatment led to an 
increase in forebrain markers, low levels of CHIR treatment led to an increase in 
expression of midbrain markers, and high levels of CHIR treatment led to an increase in 
expression of hindbrain markers. The low and high levels of CHIR treatment led to a 
more heterogeneous population containing both midbrain and hindbrain markers present 
in both. This is likely due to the fact that the levels of CHIR used during treatment were 
not optimal in modulating the levels of Wnt signaling. In the future, these levels would 
need to be adjusted. Importantly, the 0.2 uM IWP2 treated samples produced an almost 
entirely homogeneous population of anterior patterned neurons. This produced a model in 
which the specific cells affected by AD can be studied. 
3.5 Conclusion 
 Through this research, a three - dimensional hiPSC - derived organoid model has 
been developed that has laid the groundwork to begin to uncover the complex 
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pathophysiology behind Alzheimer’s disease. This model has the ability to be adapted 
using AD patient - derived hiPSCs, providing the unique opportunity to see the disease 
manifest itself in both sporadic and familial cases in an environment very similar to that 
of in vivo native tissue. Because AD is manifested within the cortex, it is imperative to 
use a population of neurons within this region to truly understand the disease. For this 
reason, the original model was adapted to determine if homogenous populations of 
forebrain, midbrain, and hindbrain neuronal cells could be differentiated in three - 
dimensions, in order to further the understanding of AD. Homogeneous neuronal 
populations were created using the 3-D differentiation, allowing for a closer look into 
disease mechanisms.  
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Figure 3-1: Summary of Endogenous WNT Signaling Using a GFP Reporter. 
Manipulating endogenous WNT signaling levels give rise to the differentiation of forebrain, midbrain, and 
hindbrain neuronal subtypes. The presence of low WNT gives rise to forebrain, the presence of middle 
levels of WNT gives rise to midbrain neurons, and the presence of high levels of WNT gives rise to 
hindbrain and spinal cord neurons30. 
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Figure 3-2. Generation of 3-D Neuronal Cultures from hPSCs. (A) Schematic of protocol for the 
generation of 3-D neuronal cultures from hPSCs. (B) Phase contrast images of 3-D aggregates at D1, D6, 
D24, and D42. (C) Quantitative PCR (qPCR) analysis for expression of neuronal-, neurotransmitter-,and 
astroglial-related markers in day 50+ (D50) differentiated cultures. (D) QPCR analysis of D50+ neuronal 
cultures generated using-specific subtype-differentiation protocols. (E) QPCR analysis of D50+ neuronal 
culture generated using cortical-specific differentiation condition. 
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CHAPTER 4: Development of a Three-Dimensional Model Using Neural Progenitor 
Cells 
4.1 Introduction 
 While the results from the 3-D hiPSC model showed some promise, the 
differentiation was not as efficient as expected. With that, it was hypothesized that 
starting with a population of cells closer to the endpoint would help to improve the 
process. Here, a 3-D model was developed using non-demented control neural progenitor 
cells. This NPC line provide the unique opportunity to model AD in three-dimensions 
and provide new insights into the disease. The relative gene expression and protein 
expression were analyzed to determine if the NPCs were differentiating into neuronal cell 
types.    
4.2 Materials and Methods 
4.2.1 Three-Dimensional Differentiation Using Non-Demented Control NPCs 
NPCs were maintained on PLO/LN coated plates until the cells reached 90% 
confluency. The NPCs were then dissociated into single cell using Accutase ® and plated 
at 1.0 x 106 cells per well on ultra-low attachment plates and placed on an orbital shaker 
at 95 RPM in a 37°C, 5% CO2 incubator. Media volume was 3 mL of NEM and 3 uL 
5mM ROCKi per well. The cells begin to form into embryoid bodies (EBs) on the first 
day. The EB media is exchanged with 2 mL fresh NEM everyday during the first seven 
days to support NPC proliferation and expansion. On the eighth day, the media is 
changed from NEM to NDM to expand the EBs.  NDM is used for 18 days, exchanging 
half of the media daily. After the NPCS have differentiated for 18 days, the media is 
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changed from NDM to NBM. Half of the media was exchanged daily (ISSN 1548-7091) 
(Fig 4-1 A-B) 
4.2.2 RT-qPCR Analysis 
 The RT-qPCR analysis followed the same protocol as previously described for the 
hiPSC 3-D models. 
4.2.3 Cryopreservation  
To maintain the 3-D structure of the differentiated EBs, cryopreservation was 
used. First, the EBs were fixed in 4% paraformaldehyde overnight. They were then 
washed with PBS and transferred to a 30% sucrose solution and kept in 4°C for 48-72 
hours. The EBs were then transferred into embedding molds with OCT compound 
(Tissue-Tek), which were then frozen using methylbutane over dry ice. A cryostat was 
used to section EBs into 10 um-thick sections.  
4.2.4 Immunohistochemistry Analysis 
 Immunohistochemistry was performed on NDC NPCs in their differentiated 
aggregate form to determine the protein expression and structure in three dimensions.  
Slides containing the aggregate sections were washed with PBS in a Coplin jar. Slides 
were then treated with a permeabilization solution for 15 minutes at room temperature in 
a Coplin jar, followed by a rinse with PBS. Excess fluid was removed and the sections 
were enclosed in a circle using a PAP pen. Blocking serum was added to the slides for 
one hour at room temperature. Slides were tapped on a paper towel to remove the excess 
blocking serum. Primary antibodies were added to the slides and incubated in a staining 
box overnight at 4°C. The slides were then rinsed with PBS and washed in PBS three 
times for 15 minutes each in a Coplin jar. Slides were tapped on a paper towel to remove 
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excess PBS. The secondary antibody was added and the slides were incubated in the dark 
at room temperature for one hour. Slides were rinsed with PBS and washed two times 
with PBS for 15 minutes each in a Coplin jar. DAPI was added for 5 minutes and the 
sections were washed PBS. Mounting solution was added and a coverslip was applied 
and sealed with clear nail polish. Slides were allowed to dry for one hour at room 
temperature in the dark. Slides could then be imaged using a fluorescent microscope. 
4.3 Results  
 Real time quantitative polymerase chain reaction was performed on the NDC NPC 3-
D samples on day 0 and two samples from day 50 onward in order to confirm that the 
NPCs were differentiating from NPCs into neurons and neuronal subtypes. 
Immunohistochemistry was also performed on the NDC NPC samples on day 50 to 
confirm the protein expression of these samples while still in the 3-D structure. First, the 
NDC NPC samples were analyzed using RT-qPCR and run through five panels of 
primers: post-mitotic neuron, neurotransmitter, astroglial, early forebrain, and mature 
cortical markers (Fig 4-1 C, E). The samples taken on day 0 show no expression of post-
mitotic neurons, neurotransmitter, astroglial markers, early forebrain, or mature cortical 
markers. The samples taken on day 50 onwards show mid to high expression post-mitotic 
neuron markers, specifically RBFOX3 and TUBB3 (Fig 4-1 C). The day 50 onward 
samples also show mid to high levels of expression of neurotransmitter markers, 
specifically GABRA, SLC17A7, and SLC6A4. The day 50 onward samples also show 
mid levels of expression of astroglial markers EAAT2, GFAP, and MBP. Importantly, the 
NDC NPCs were able to produce neurons that express early forebrain and mature cortical 
markers (Fig 4-1 E) without needing to pattern them. The NDC NPC 3-D samples were 
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then analyzed using immunohistochemistry in order to determine protein expression. The 
NDC NPC 3-D aggregates were stained for post-mitotic neuronal (NESTIN, RBFOX3, 
TUBB3) and astroglial markers (GFAP) on day 50 cultures (Fig 4-1 D). It can be seen 
that the samples are stained positively for all four of these markers. The protein 
expression of a forebrain marker, FOXG1, was also analyzed on day 50 and it can be 
seen that the sample is expressing this (Fig 4-1 F). 
4.4 Discussion  
 Through hiPSC modeling of Alzheimer’s disease, the pathophysiology begins to be 
understood, but the techniques have not provided an optimal system for modeling the 
disease. The hiPSC 2-D models do not allow for the development of AD hallmarks and 
the hiPSC 3-D models did not efficiently differentiate hiPSCs into neuronal cell types. 
Thus, AD remains elusive in its development and a better model needed to be developed. 
Thus, a 3-D NPC organoid model was created, as NPCs are closer to the final lineage and 
are biased to a forebrain fate. A control neural progenitor cell line, NDC NPC, was used 
in the development of this 3-D NPC organoid model to determine if the three-
dimensional organoid protocol could be used with NPCs and optimized to produce a 
higher efficiency of cells being differentiated into neurons, astroglia, and 
neurotransmitters. It was found through RT-qPCR as well as immunohistochemistry that 
the NDC NPC EBs expressed high levels of post-mitotic neuronal, astroglial, and 
neurotransmitter markers. It was also found that the NDC NPCs differentiated into a high 
population of neurons with anterior identity. It was found that beginning with a 
population of pure NPCs leads to a higher efficiency in differentiation.  
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4.5 Conclusions 
 Here, a three-dimensional model of Alzheimer’s disease using hiPSCs was developed 
and then adapted for the use of NPCs. This NPC model provides the ability to use 
patient-derived hiPSCs that are then differentiated into a pure population of NPCs. Once 
these NPC lines are created, the 3-D differentiation can be used to study the pathogenesis 
of AD. The differentiation protocol for the diseased cell lines needs to be optimized 
further in order to uncover information about AD.  
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Figure 4-1. Generation of 3-D Neuronal Cultures from hNPCs. (A) Schematic of protocol for 
generation of 3-D neuronal cultures from hNPCs. (B) Phase contrast images of hNPCs as well as D1, D7, 
and D25 3-D aggregates. (C) QPCR analysis for expression of neuronal-, neurotransmitter-, and astroglial-
related markers in day 50+ (D50) differentiated cultures. (D) Immunofluorescence for post-mitotic 
neuronal (NESTIN, RBOX3, TUBB3) and astroglial markers (GFAP) in D50+ neuronal cultures. (E) 
QPCR analysis for expression of early forebrain and mature cortical markers in D50+ neuronal cultures. (F) 
Immunofluorescence analysis for FOXG1 in D50+ neuronal cultures. 
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CHAPTER 5: Conclusions and Future Work 
5.1 Conclusions 
 The overall goal of this research was to develop a robust and adaptable platform in 
which to model Alzheimer’s disease. A three-dimensional organoid - based system was 
chosen over other 3-D platforms, such as hydrogels, due to the fact that organoids are 
self-organizing and better recapitulate the in vivo native tissue in which AD is developed. 
First, a 3-D organoid model was developed using hiPSCs.  After it was determined that 
the hiPSCs could differentiate in this 3-D platform, the aim was to more closely mimic 
the in vivo environment in which AD occurs. In order to accomplish this, the Wnt 
pathway was modulated to generate a homogeneous population of hiPSCs of anterior 
identity, where AD is developed. This gives a closer look at the region in which the brain 
is affected by AD. The hiPSC protocol was then adapted for use with NPCs due to the 
fact that NPCs are closer developmentally to neurons and are biased towards a forebrain 
fate. In doing so, a control line, NDC NPC, was differentiated in 3-D. The NDC NPC line 
showed much higher expression of neuronal, astroglial, and neurotransmitter markers 
than did the hiPSC line, and also expressed numerous anterior neuronal markers. These 
results show that the 3-D protocol using NPCs is successful in efficiently differentiating 
cells into the neuronal cell types as well as in the region of interest. The 3-D NPC 
protocol allows for a higher efficiency of differentiation as well as a shorter amount of 
time to do so. For these reasons, the focus of the research has been shifted to using 
various NPC lines. Through the research that was conducted during my thesis, a three-
dimensional model of Alzheimer’s disease was developed and then optimized for highly 
efficient differentiation of NPCs into neuronal subtypes. This research provides an in 
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vitro model that recapitulates the complexities of AD and can be used to study disease 
mechanisms and develop therapies.  
5.2 Future Work  
 In order to better characterize the cells that are being differentiated with the various 3-
D models presented within this research, various assays need to be performed. The first 
assay to characterize the neurons is electrophysiology. There have been attempts to patch 
clamp the differentiated hiPSCs and NPCs in order to determine if they are firing action 
potentials, but they have remained unsuccessful. Differentiated neurons have been taken 
from their 3-D state and replated onto 2-D cultures and then patch clamped. It is 
hypothesized that during this replating process, the neuronal synaptic network may be 
disrupted, causing no action potentials to be detected. Different methods are being 
explored on measuring these action potentials, including MEA. The next goal going 
forward is to adapt this protocol for use with diseased cell lines. This will allow the study 
of the pathophysiology of both the sporadic and familial cases of Alzheimer’s disease. 
Once these diseased lines are in culture, assays that characterize the extent of AD 
hallmarks will need to be performed.  
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